

Drug Repurposing Guidebook

Building Block 1448

This document defines the content of the FACT SHEET to be created for each identified tool, incentives, initiative or practice (the Building Block) introduced by public bodies or used by developers to expedite drug repurposing in Rare Diseases (RDs).

ITEM	DESCRIPTION
Building Block (BB) Title	Funding Sources for Drug Repurposing
References	https://www.cureswithinreach.org/programs/funding-opportunities-rfps/
	https://www.bmbf.de/bmbf/shareddocs/bekanntmachungen/de/2022/07/2022-07-15-Bekanntmachung-Biomedizin.html
	https://ec.europa.eu/info/funding- tenders/opportunities/portal/screen/opportunities/topic-details/horizon-hlth- 2021-disease-04-02
	https://grants.nih.gov/grants/guide/pa-files/PAR-20-301.html
	https://grants.nih.gov/grants/guide/pa-files/PAR-20-161.html
	https://www.zonmw.nl/nl/onderzoek-resultaten/geneesmiddelen/drug-rediscovery/
Description	Different forms of public and private funding are available from national and international funding organizations, such as the European Commission, the National Institutes of Health, which are either specific to drug repurposing for rare diseases or have this as a priority. This research, innovation and implementation funding is available for (multi-)national collaboration projects as well as for individual researchers and supports SMEs.
Category	Funding
Type of BB	Development resource
Geographical scope	International



ITEM	DESCRIPTION
Availability	Applicants identifying, testing and implementing drug repurposing candidates
Scope of use	To provide funding for researchers from academia and industry for different phases of drug repurposing
Stakeholders involved	Researchers from academia and industry Public and philanthropic funders, for example the European Commission, National Insitute of Health, LifeArc EMA, FDA, PMDA
Enablers/ Requirements	To meet the requisites established in the funding competitive call.
Output	A successful funding application results both in a research proposal and the means to conduct the research through a potential public-public or public-private partnership.
Best time to apply and time window	The tool has the best perspectives / results in the very early phases of drug repurposing.
Expert tips	Start applying for funding well in advance, and also consider alternative funding options. Different partners together can apply to a combination of funding sources. PROs:
	 Allows a substantial amount of funding, when obtained, especially for early phases of drug development. Start planning for additional funding for each phase of development.
	Anticipate IP issues in the funding agreement
	CONs: — High commitment is required from participants, while only a part of proposals
	gets granted.

